• All
  • News
  • Press Releases

Bridge to Life Reintroduces EasiSlush® to the US Market, Meeting High Demand for Easy-to-Use Sterile Slush for Organ Transplantation

Bridge to Life Ltd, a leading provider of organ preservation solutions, today announces the return of EasiSlush ™ to the US market, effective immediately. With its unmatched ease of use, high quality and portability, EasiSlush has become the preferred choice for organ transplant professionals who are responsible for transporting life-giving organs from donors to recipients under critical timelines.

Bridge to Life Achieves ISO 13485:2016 Certification, Reinforcing Commitment to Quality and Safety in Hypothermic Oxygenated Perfusion and Cold Flush Organ Preservation Solutions

Bridge to Life Ltd, a renowned market leader in cold flush organ preservation solutions, is proud to announce its recent certification for ISO 13485:2016. This achievement further solidifies the company’s commitment to maintaining exceptional standards of quality and safety in its premier products, including Belzer UW, EasiSlush® and VitaSmart™ Machine Perfusion System (Europe).

Bridge to Life Divests Certain Assets to TransMedics

Bridge to Life Ltd. announced today its divestiture of certain assets to TransMedics, Inc., a wholly owned subsidiary of TransMedics Group, Inc., including its EVOSS heart and lung and LifeCradle heart perfusion assets.

ADVANCING TRANSPLANTATION TECHNOLOGIES: Bridge to HOPE Trial Demonstrates Promising Findings with Hypothermic Oxygenated Perfusion

Bridge to Life Ltd. announced results from interim analysis of its multicenter, randomized, controlled liver clinical trial presented at the 2023 American Transplant Congress (ATC).

Early Closure of Bridge to Life Ltd. HOPE Liver Trial Enrollment Affirms the Potential of Hypothermic Oxygenated Perfusion

Bridge to Life, Ltd. announced that it met positive criteria from interim analysis for early enrollment closure of its multicenter, randomized, controlled Bridge to HOPE Liver Clinical Trial.

Bridge to Life Ltd. Names New Chief Financial Officer and Vice-President of Operations

Bridge to Life, Ltd. announced the expansion of their executive leadership team by appointing Bob Beechey as Chief Financial Officer and Blago Herrera as Vice President of Operations.

Bridge to Life Ltd. Announces Early Results from its Pivotal Bridge to HOPE Liver Clinical Trial

Bridge to Life, Ltd. announced early results from its multicenter, randomized, controlled Bridge to HOPE Liver Clinical Trial.

Bridge to Life Ltd. Names Don Webber as President and CEO

Steve Schweighardt, founder and former CEO to retire from daily operations but will remain as Chairman of the Board.

Bridge to Life Ltd. Receives Breakthrough Device Designation from the FDA

Bridge to Life advances their perfusion system development with the breakthrough device designation for the LifeCradle® Heart Preservation Transport system.

Bridge to Life Ltd. Announces First Enrollment and Orthotopic Liver Transplantation in its Pivotal Bridge to HOPE Liver Clinical Trial

Bridge to Life Ltd., a leading global supplier of organ preservation solutions and organ perfusion technologies, announced first enrollment and orthotopic liver transplantation in its U.S. pivotal Bridge to HOPE Liver Clinical Trial.

Bridge to Life Ltd. Receives Investigational Device Exemption Approval from the FDA

The primary endpoint for the trial is the rate of early allograft dysfunction between treatment groups; additional key endpoints include rates of ischemic cholangiopathy and patient and graft survival up to 1-year post-transplantation. 

Bridge to Life Announces First Close of $56 Million Growth Financing Led by Perceptive Advisors

Bridge to Life, Ltd., a leading global supplier of organ preservation solutions and organ perfusion technologies, announced the first closing of a growth financing, totaling $56 million, led by Perceptive Advisors, a leading life sciences investment firm.

Bridge to Life CEO Stevan Schweighardt Featured in CEOCFO Magazine

Bridge to Life Chairman & CEO Stevan Schweighardt was interviewed in a feature piece for CEOCFO Magazine. He discusses the challenges of the transplant field and Bridge to Life’s current and upcoming solutions to make organ transplantations more successful.

Bridge to Life and Tevosol Merge to Commercialize Portable Normothermic Machine Preservation Technology Platform for Organ Transplantation

Bridge to Life, Ltd., a leading global supplier of organ preservation solutions and organ perfusion technologies, and Tevosol, Inc., a clinical stage medical device startup, today announced their merger to develop and commercialize groundbreaking new products for the organ transplantation community. The arrangement includes Bridge to Life’s significant financial commitment to manufacture, trial, and launch Tevosol’s portable ex-vivo lung perfusion (EVLP) machine and normothermic organ preservation platform.

Watch ILTS Insights Webinar Series Sponsored by BTL

Bridge to Life is proud to have sponsored two webinars in the ILTS Insights series. Each webinar can be watched below.